Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Sun Pharmaceutical Industries announced Q1FY25 results: Gross sales at Rs 1,25,245 million, growth of 6.3% India Formulation sales at Rs 41,445 million, up 16.4% US Formulation sales at USD 466 million, lower by 1.0% Global Specialty sales at USD 266 million, up 14.7% Global Specialty sales accounted for 17.7% of Q1FY25 sales Emerging Markets Formulation sales at USD 284 million, up by 8.8% Rest of World Formulation sales at USD 190 million, down by 2.9% R&D; investments at Rs 7,940 million compared to Rs 6,796 million for Q1FY24 EBITDA at Rs 36,076 million (including other operating revenues), up 8.3%. EBITDA margin for Q1 at 28.5% vs 27.9% during Q1FY24. Net profit for Q1FY25 was Rs 28,356 million, up 40.2% YoY; up 20.9% over adjusted net profit of Q1FY24. Dilip Shanghvi, Chairman and Managing Director of the Company said, “Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe and the completion of acquisition of Taro minority shares. These steps advance our innovative as well as generic business offerings, and will help us serve patients better.” Result PDF